Is SB Financial Group, Inc. (SBFG) Stock a Buy after Anthony Cosentino’s Insider Transaction?; 9 Bullish Analysts Covering Loxo Oncology, Inc. (LOXO)

Anthony Cosentino, an insider and also EVP & CFO of the popular company Sb Financial Group Inc made a purchase. He purchased 2,777 shares of the firm with Anthony Cosentino’s transaction worth approx. $49,986 U.S. Dollars – totalled based on $18.0 a share. Right now, Anthony Cosentino owns 10,511 shares which are equivalent to about 0.16% of the company’s total market cap. Anthony Cosentino’s transaction was executed on 16/02/2018 and was revealed inside a document at the Washington-based Security and Exchange Commission’s website.

Among 10 analysts covering Loxo Oncology Inc (NASDAQ:LOXO), 9 have Buy rating, 1 Sell and 0 Hold. Therefore 90% are positive. Loxo Oncology Inc had 30 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, June 5 by Citigroup. As per Tuesday, August 29, the company rating was downgraded by JMP Securities. As per Friday, August 28, the company rating was upgraded by Zacks. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) earned “Overweight” rating by Morgan Stanley on Friday, October 6. The firm has “Buy” rating given on Wednesday, November 11 by Stifel Nicolaus. The company was initiated on Wednesday, February 8 by Jefferies. The firm has “Buy” rating by Citigroup given on Thursday, November 16. Citigroup maintained the shares of LOXO in report on Wednesday, March 16 with “Buy” rating. The company was initiated on Friday, January 15 by Citigroup. The firm has “Buy” rating given on Monday, June 5 by BTIG Research. See Loxo Oncology, Inc. (NASDAQ:LOXO) latest ratings:

20/12/2017 Broker: BTIG Research Rating: Buy New Target: $102.0 Maintain
28/11/2017 Broker: William Blair Rating: Outperform Initiates Coverage On
16/11/2017 Broker: Citigroup Rating: Buy Old Target: $112 New Target: $108 Maintain
14/11/2017 Broker: JMP Securities Rating: Buy New Target: $95.0 Upgrade
14/11/2017 Broker: IFS Securities Old Rating: Outperform New Rating: Strong Buy Upgrade
02/11/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $104.0 Maintain
20/10/2017 Broker: Citigroup Rating: Buy New Target: $112.0 Maintain
06/10/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $95 New Target: $103 Maintain
27/09/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $94.0 Maintain
29/08/2017 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Perform Downgrade

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $3.12 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

Since August 14, 2017, it had 0 insider purchases, and 18 selling transactions for $70.60 million activity. $226,753 worth of Loxo Oncology, Inc. (NASDAQ:LOXO) shares were sold by Van Naarden Jacob. AISLING CAPITAL III LP had sold 250,000 shares worth $20.13 million. Bonita David P also sold $20.63 million worth of Loxo Oncology, Inc. (NASDAQ:LOXO) on Friday, December 8. Burstein Jennifer also sold $141,554 worth of Loxo Oncology, Inc. (NASDAQ:LOXO) on Thursday, December 14. Another trade for 250,000 shares valued at $20.63 million was sold by ORBIMED ADVISORS LLC. Flaherty Keith T. sold $523,883 worth of stock or 7,250 shares. Another trade for 15,000 shares valued at $1.10M was made by Bilenker Joshua H. on Monday, August 14.

Investors sentiment decreased to 1.73 in 2017 Q3. Its down 2.10, from 3.83 in 2017Q2. It dropped, as 13 investors sold Loxo Oncology, Inc. shares while 35 reduced holdings. 31 funds opened positions while 52 raised stakes. 29.06 million shares or 49.34% less from 57.37 million shares in 2017Q2 were reported. Bankshares Of America Corporation De invested in 13,769 shares. Axa holds 0.04% or 97,635 shares in its portfolio. Opaleye holds 4.23% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO) for 130,000 shares. Dekabank Deutsche Girozentrale invested 0.01% in Loxo Oncology, Inc. (NASDAQ:LOXO). Wellington Mgmt Gru Limited Liability Partnership invested 0.05% in Loxo Oncology, Inc. (NASDAQ:LOXO). Fifth Third Bankshares accumulated 0% or 240 shares. Amundi Pioneer Asset Management reported 101,516 shares. Morgan Stanley holds 0% or 57,607 shares. Invesco accumulated 57,430 shares or 0% of the stock. Peak6 Limited Partnership, Illinois-based fund reported 398 shares. Pictet Asset Management Ltd reported 241,402 shares stake. Amer has invested 0% in Loxo Oncology, Inc. (NASDAQ:LOXO). New York-based Laurion Cap Mgmt Ltd Partnership has invested 0% in Loxo Oncology, Inc. (NASDAQ:LOXO). Citigroup stated it has 2,145 shares or 0% of all its holdings. Moreover, Baker Bros Advsr Limited Partnership has 0.07% invested in Loxo Oncology, Inc. (NASDAQ:LOXO).

The stock decreased 0.59% or $0.62 during the last trading session, reaching $104.35. About 33,345 shares traded. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 77.12% since February 16, 2017 and is uptrending. It has outperformed by 60.42% the S&P500.

The stock increased 0.76% or $0.14 during the last trading session, reaching $18.48. About 133 shares traded. SB Financial Group, Inc. (NASDAQ:SBFG) has risen 63.81% since February 16, 2017 and is uptrending. It has outperformed by 47.11% the S&P500.

SB Financial Group, Inc., through its subsidiaries, provides banking and wealth management services to individual and corporate clients in northwest Ohio and northeast Indiana. The company has market cap of $119.37 million. It accepts deposits, such as checking accounts, savings accounts, money market accounts, demand deposits, NOW accounts, and time certificates of deposit. It has a 10.61 P/E ratio. The company's loan products include commercial and agricultural, commercial real estate, residential mortgage, and consumer loans.

Since September 7, 2017, it had 2 buys, and 0 selling transactions for $5,355 activity. Another trade for 175 shares valued at $3,089 was bought by STOLLY TIMOTHY J..

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: